Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study

Journal of Rheumatology

Volumn 44, Issue 8, 2017, Pages 1165-1172

  Taraborelli, Mara ^a   Reggia, Rossella ^a   Dall'Ara, Francesca ^a   Fredi, Micaela ^a   Andreoli, Laura ^a   Gerosa, Maria ^a   Hoxha, Ariela ^a   Massaro, Laura ^a   Tonello, Marta ^a   Costedoat Chalumeau, Nathalie ^a   Cacoub, Patrice ^a   Franceschini, Franco ^a   Meroni, Pier Luigi ^a   Piette, Jean Charles ^a   Ruffatti, Amelia ^a   Valesini, Guido ^a   Harris, Eon Nigel ^a   Tincani, Angela ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; BLEEDING; CANCER DIAGNOSIS; COMORBIDITY; CONNECTIVE TISSUE DISEASE; DEMOGRAPHY; DISEASE COURSE; DRUG USE; FATALITY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; ORGAN INJURY; OUTCOME ASSESSMENT; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RECURRENT DISEASE; RETROSPECTIVE STUDY; SEROLOGY; THROMBOSIS; CLINICAL TRIAL; COMPLICATION; DISEASE EXACERBATION; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85027836354     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.161364     Document Type: Article

References (31)

1. Hughes GR. The anticardiolipin syndrome. Clin Exp Rheum 1985;3:285-6.
2. Grika EP, Ziakas PD, Zintzaras E, Moutsopoulos HM, Vlachoyiannopoulos PG. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol 2012;39:516-23.
3. Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramon E, et al; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis 2015;74:1011-8.
4. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
5. Taraborelli M, Andreoli L, Tincani A. Much more than thrombosis and pregnancy loss: The antiphospholipid syndrome as a 'systemic disease'. Best Pract Res Clin Rheumatol 2012;26:79-90.
6. Erkan D, Yazici Y, Sobel R, Lockshin MD. Primary antiphospholipid syndrome: Functional outcome after 10 years. J Rheumatol 2000;27:2817-21.
7. Gomez-Puerta JA, Martin H, Amigo MC, Aguirre MA, Camps MT, Cuadrado MJ, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: Do they develop lupus?. Medicine 2005;84:225-30.
8. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011;20:206-18.
9. Munoz-Rodriguez FJ, Font J, Cervera R, Reverter JC, Tassies D, Espinosa G, et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 1999;29:182-90.
10. Krnic-Barrie S, O'Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997;157:2101-8.
11. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332:993-7.
12. Rosove MH, Brewer PM. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303-8.
13. Garcia-Carrasco M, Galarza C, Gomez-Ponce M, Cervera R, Rojas-Rodriguez J, Espinosa G, et al. Antiphospholipid syndrome in Latin American patients: Clinical and immunologic characteristics and comparison with European patients. Lupus 2007;16:366-73.
14. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: Understanding the antibodies. Nat Rev Rheumatol 2011;7:330-9.
15. Hernandez-Molina G, Espericueta-Arriola G, Cabral AR. The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome. Clin Exp Rheumatol 2013;31:382-8.
16. Bazzan M, Vaccarino A, Stella S, Sciascia S, Montaruli B, Bertero MT, et al. Patients with antiphosholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study). Lupus 2016;25:479-85.
17. Palareti G, Antonucci E, Lip GY, Testa S, Guazzaloca G, Falanga A, et al; START-Register Participants. The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study. Thromb Haemost 2016;115:1101-8.
18. Cervera R; CAPS Registry Project Group. Catastrophic antiphospholipid syndrome (CAPS): Update from the 'CAPS Registry'. Lupus 2010;19:412-8.
19. Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017;76:476-85.
20. Alba P, Gomez-Puerta JA, Goycochea-Robles MV, Amigo MC. Organ damage and quality of life in antiphospholipid syndrome. Curr Rheumatol Rep 2016;18:7.
21. Tincani A, Taraborelli M, Cattaneo R. Antiphospholipid antibodies and malignancies. Autoimmun Rev 2010;9:200-2.
22. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-81.
23. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al; Euro-Phospholipid Project Group. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1, 000 patients. Arthritis Rheum 2002;46:1019-27.
24. Asherson RA, Baguley E, Pal C, Hughes GR. Antiphospholipid syndrome: Five year follow up. Ann Rheum Dis 1991;50:805-10.
25. Ceribelli A, Tincani A, Cavazzana I, Franceschini F, Cattaneo R, Pauley BA, et al. Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS). Autoimmunity 2011;44:90-7.
26. Smeenk RJ, Lucassen WA, Swaak TJ. Is anticardiolipin activity a cross-reaction of anti-DNA or a separate entity?. Arthritis Rheum 1987;30:607-17.
27. Andreoli L, Pregnolato F, Burlingame RW, Allegri F, Rizzini S, Fanelli V, et al. Antinucleosome antibodies in primary antiphospholipid syndrome: A hint at systemic autoimmunity?. J Autoimmun 2008;30:51-7.
28. Piette JC, Wechsler B, Frances C, Papo T, Godeau P. Exclusion criteria for primary antiphospholipid syndrome. J Rheumatol 1993;20:1802-4.
29. de Carvalho JF, Caleiro MT, Vendramini M, Bonfa E. Clinical and laboratory evaluation of patients with primary antiphospholipid syndrome according to the frequency of antinuclear antibodies (ANA Hep-2). Rev Bras Reumatol 2010;50:262-72.
30. Freire PV, Watanabe E, dos Santos NR, Bueno C, Bonfa E, de Carvalho JF. Distinct antibody profile: A clue to primary antiphospholipid syndrome evolving into systemic lupus erythematosus?. Clin Rheumatol 2014;33:349-53.
31. Tincani A, Allegri F, Balestrieri G, Reber G, Sanmarco M, Meroni P, et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004;114:553-8.